Podcasts about Boehringer Ingelheim

In this episode, Sierra Garvin, Senior Associate Director of Above Brand Marketing at Boehringer Ingelheim speaks with Mandy Leonard, Senior Director of Drug Use Policy and Formulary Management at Cleveland Clinic about the key drivers of rising healthcare costs, including chronic disease, multiple comorbidities, rare diseases, and wasteful spending. They explore practical strategies to lower total cost of care while maintaining quality and improving patient outcomes.This episode is sponsored by Boehringer Ingelheim.

'One FM' by One MSL strives to connect voices within the global Field Medical community.For episode 16 Helen was joined by Wade May, Global Capability Owner - Learning, Training & Coaching (FLM & MSL), Boehringer Ingelheim.If you would like to feature on a future episode, please email community@onemsl.comhttps://www.onemsl.com/

Over 1.5million adults in the UK tried weight loss drugs in 2024-25. Many swear by them, but they have been associated with side effects including nausea and, in some cases, extremely painful gallstones. But what does the evidence actually tell us, and what is the wider impact on the way we view our bodies in society?James Gallagher is joined by Professor of Cardiometabolic Medicine at the University of Glasgow Naveed Sattar, Dr Beverley O'Hara, Lecturer in Public Health Nutrition at Leeds Beckett University, and Dr Margaret McCartney, resident Inside Health GP. They discuss what the evidence tells us about the potential known side effects of these weight loss drugs, and the potential impact their use has on our view of obesity as a society. We also hear from Sarah Le Brocq, who has struggled with obesity all her adult life and has been on these drugs for the past 2-3 years about her experiences. Margaret McCartney has no conflicts of interest to declare.Beverley O'Hara has no conflicts of interest to declare. She has 2 roles with the Association for the Study of Obesity (voluntary academic positions).Naveed Sattar has consulted for and/or received speaker honoraria from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gan & Lee, GlaxoSmithKline, Hanmi Pharmaceuticals, Kailera, Mass Medicines, Menarini-Ricerche, Metsera, Novo Nordisk, Pfizer, Regeneron, Roche, UCB Pharma, and Verdiva Bio; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche.Presenter: James Gallagher Producer: Hannah Fisher Researcher: Tom Hunt Production coordinator: Stuart Laws Content Editor: Ilan Goodman

AABP Executive Director Dr. Fred Gingrich is joined by Dr. Bob Van Saun, professor and extension veterinarian at Penn State University. He is also a member of the AABP Nutrition Committee. If you are interested in beef or dairy nutrition, consider joining the committee by visiting this page.  This episode of Have You Herd? is sponsored by Boehringer Ingelheim and the PYRAMID(R) Line of vaccines, a premier choice to protect calves from BRD. Get relentless protection at PyramidVaccines.com. Van Saun begins by reviewing the important biologic role of copper for ruminants and why it is a critical mineral for ruminants. We also discuss some clinical diseases or conditions where a veterinarian may be triggered to look at a copper deficiency. This includes bleaching of the haircoat (achromotrichia), anemia, reproductive performance, growth, and disease consequences due to the role copper plays in innate and humoral immunity. Some of these syndromes may be clinically apparent, but a large portion may be subclinical, and the practitioner should evaluate the entirety of the mineral program to evaluate.  Van Saun discusses the interplay between copper and other minerals and how this interaction can affect copper metabolism. We also discuss general guidelines copper in ruminants and diagnostic procedures for evaluating copper metabolism in a herd.  Due to the impacts of copper on many production and disease issues in ruminants, veterinarians play a critical role in evaluating herds for copper deficiencies by performing a diagnostic work-up and evaluating potential interventions.  

Befarar du att du kommer att förlora ditt jobb till AI?  Eller, är du ivrig att bli av med arbete som en AI skulle kunna göra istället? Dagens avsnitt av Klart! handlar om en sak du kan göra för att ligga steget före i AI-omdaningen av vårt arbete. Vad är den senaste uppgiften som du nu låter en AI göra? Berätta för mig och inspirera mig till att göra detsamma också jag! Se vad jag svarade när en medarbetare på Boehringer-Ingelheim frågade hur lång tid det tar att komma igång med en ny list-app! Klart! finns också som veckobrev till din mejl, för dig som hellre läser än lyssnar (eller gör både och!). David Stiernholm är struktör. Han hjälper människor och företag att bli mer effektiva genom att skapa bättre ordning och struktur. Hans motto: allting kan göras enklare! David är flitigt anlitad som föreläsare av allt från väletablerade storföretag till entreprenörsföretag i stark tillväxt. Han utmärker sig genom sina superkonkreta verktyg och metoder som du direkt kan använda på jobbet och hemma. Under en föreläsning med David Stiernholm upptäcker du att struktur är både befriande och roligt. Och att du blir mindre stressad och mer effektiv.

This episode covers: Cardiology This Week: A concise summary of recent studies Atrial septal defects in adults Conservative and invasive management of chronic coronary syndromes Milestones: 4S trial   Host: Rick Grobbee Guests: JP Carpenter, Annemien van den Bosch, Rasha Al-Lamee, Roxana Mehran Want to watch the episode? Go to: https://esc365.escardio.org/event/2552 Want to watch the extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc., Population Health Research Institute (PHRI), Protembis GmbH, Radcliffe, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ; personal fees from: None ; Equity

Host: Rick Grobbee Guest: Annemien van den Bosch Want to watch that extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2552 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson

Doctors Lisa and Sara talk to Consultant Endocrinologist Dr Rupinder Kochhar about patients with Type 2 Diabetes. Using hypothetical cases, we talk a little bit about diagnosis, but spend most of the time discussing the details of management in younger patients as well as how to de-escalate treatment and what the goals might be in a more frail elderly patient. Disclaimer: All educational content in this podcast was developed as part of the Circulation Health collaborative working project between Boehringer Ingelheim Limited, Greater Manchester Primary Care Provider Board and Health Innovation Manchester. Content has been created by Circulation Health Clinical Leads for educational purposes, reflecting NHS Clinical Lead and guideline-based recommendations. Boehringer Ingelheim had no input into content development. They have provided financial resources to support Podcast recordings related to this project. You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: NICE draft guideline - Type 2 diabetes in adults: management: https://www.nice.org.uk/guidance/gid-ng10336/documents/450 Managing Heart Failure, CKD and T2DM in Primary Care: https://pckb.org/e/managing-heart-faiure-ckd-and-t2dm-in-primary-care/ Essential steps in primary care management of older people with Type 2 diabetes: an executive summary on behalf of the European geriatric medicine society (EuGMS) and the European diabetes working party for older people (EDWPOP) collaboration: https://pmc.ncbi.nlm.nih.gov/articles/PMC10628003/ Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes: https://diabetesjournals.org/care/article/45/11/2753/147671/Management-of-Hyperglycemia-in-Type-Diabetes Diabetes UK: https://www.diabetes.org.uk/ ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

In this special series on Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated steatohepatitis (MASH) our host, Dr. Neil Skolnik will discuss diagnosis and treatment of MASH using a case-based approach with two master clinicians, one a hepatologist and the other a primary care physician. This special episode is supported by an independent educational grant from Boehringer Ingelheim. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Alina M. Allen, M.D. Associate Professor of Medicine at Mayo Clinic in Rochester, Minnesota, where she serves as the Director of Hepatology and Director of the MASLD Clinic. Susan Kuchera, M.D. - Program Director of the Jefferson Health Abington Family Medicine Residency Program, Clinical Associate Professor of Family and Community Medicine in the Sidney Kimmel Medical College of Thomas Jefferson University Selected references: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care 2025;48(7):1057–1082  

(Note: the deadline for submitting scientific papers for the AAEP Convention is March 1, not March 15 as mentioned in the podcast.) In this episode of AAEP's Practice Life podcast, hosts Jessica Dunbar and Travis Boston engage with AAP leadership, including David Foley, Sarah Reuss, and Eric Mueller. They discuss the roles and responsibilities of AAEP leaders, reflect on the past convention, and outline future strategic plans. The conversation highlights the importance of member engagement, educational offerings, and advocacy efforts within the equine veterinary community. The leaders share insights on how to get involved and the various resources available to members, emphasizing the AAEP's commitment to supporting equine health and veterinary professionals.   Sponsored by: AAEP Practice Life is sponsored by Boehringer Ingelheim. Visit them at https://bi-animalhealth.com/equine/ 

AABP Executive Director Dr. Fred Gingrich discusses colostrum management programs with Dr. Lisa Gamsjäger, Assistant Professor at North Carolina State University.  This episode of Have You Herd? is sponsored by Boehringer Ingelheim and the PYRAMID(R) line of vaccines, a premier choice to protect calves from BRD. Get relentless protection at PyramidVaccines.com. According to research studies, approximately 30% of beef calves have failure of passive transfer and are below 10 g/L of IgG. These calves are 8x more likely to have a disease and 19x more likely to experience mortality. There may be some fundamental differences in colostrum for beef calves, and management strategies between the two production systems are vastly different which can present unique challenges for beef producers. Veterinarians are in a unique position to provide consultation to their beef clients to be prepared to intervene with assistance and/or providing a colostrum replacement product. We discuss a study that examined various feeding protocols of colostrum replacer and its impacts on passive transfer, morbidity, mortality and average daily gains. We also discuss areas for future research on beef calf colostrum management and replacement products. Veterinarians should prepare their clients for the upcoming calving season to ensure that calves receive appropriate passive transfer of immunity by proactively discussing these strategies. References:Gamsjäger L, Haines DM, Pajor EA, Lévy M, Windeyer MC. Impact of volume, immunoglobulin G concentration, and feeding method of colostrum product on neonatal nursing behavior and transfer of passive immunity in beef calves. Animal 2021. https://doi.org/10.1016/j.animal.2021.100345 Mitman SL, Jenkins H, Chamorro MF, Mzyk DA, Foster DM, Gamsjäger L. Impact of 3 colostrum replacement strategies on immunoglobulin G absorption efficiency, passive immunity, health, and growth in beef calves. J Am Vet Med Assoc. July 2025. https://doi.org/10.2460/javma.25.03.0139 Gamsjäger L, Haines DM, Pajor EA, Lévy M, Campbell J, Windeyer MC. Total and pathogen-specific serum Immunoglobulin G concentrations in neonatal beef calves, Part 1: Risk factors. Prev Vet Med. November 2023. https://doi.org/10.1016/j.prevetmed.2023.106026 Gamsjäger L, Haines DM, Pajor EA, Lévy M, Campbell J, Windeyer MC. Total and pathogen-specific serum Immunoglobulin G concentrations in neonatal beef calves, Part 2: Associations with health and growth. Prev Vet Med. November 2023. https://doi.org/10.1016/j.prevetmed.2023.105993        

Talking to the spectacular Octavia Spencer - Jane's very special guest is Octavia Spencer, the Academy Award and Golden Globe- winning actor, and iconic star of stage and screen. You all know her from her powerful, trailblazing roles in The Help, Hidden Figures and The Shape of Water, to name but three of her unforgettable films. Among her other accolades and accomplishments, she has her own star on the Hollywood Walk of Fame and is also a prolific producer with many projects in the works, as well as a best-selling author of children's books. On this segment, Octavia talks about what it felt like when she won her Oscar and was honored with a star on the Walk of Fame, her upbringing as one of seven children, her family values, and how she was able to overcome any negativity on the road to her stunning success. Octavia and Jane then discuss the public health campaign, Detect the SOS, that she is embarking on along with Sofia Vergara, Boehringer Ingelheim, the American Diabetes Association, the National Kidney Foundation, WomenHeart, and The Mended Hearts, Inc.  As part of this mission, she and Sofia want to elevate awareness to uncover hidden risks for chronic kidney disease and related cardiovascular events like heart attack or stroke with the help of a simple, non-invasive screening test. The campaign, in fact, with both stars, was featured on a spot during this year's Super Bowl.

AABP Executive Director Dr. Fred Gingrich discusses how veterinarians can get involved with semen selection strategies for their clients. Guests for this episode include Dr. Julie Adamchick, post-doctoral candidate at Cornell University and AABP liaison to the Council for Agricultural Science and Technology (CAST), Dr. Daryl Nydam, Professor of Dairy Production and Health Management at Cornell University and incoming AABP Vice-President, and Dr. Michael Capel, Perry Veterinary Clinic and Past-President of AABP. This episode of Have You Herd? is sponsored by Boehringer Ingelheim and the PYRAMID(R) line of vaccines, a premier choice to protect calves from BRD. Get relentless protection at PyramidVaccines.com. Advances in youngstock management and reproduction programs has provided an opportunity for dairy producers to utilize gender-selected semen to maintain the correct number of replacement heifers while taking advantage of the increased revenue from the sale of beef-on-dairy calves. Producers should develop a strategy with their dairy clients to plan three years in advance for the number of replacement heifers the herd will require. The veterinarian can play a role in not only assisting with implementation of these programs, but also monitoring reproductive performance and semen selection strategy monitoring to ensure success. The value that is added from maximizing beef-on-dairy calves produced can be equivalent to $2-$3 per cwt of milk. Our guests also provide tips for avoiding pitfalls and what to discuss with clients during the implementation and monitoring phase of this program.  Cornell University has developed a tool to assist veterinarians in consulting with clients on use of gender-selected and beef semen in their herds. You can find Semen Solver 2.0 at this link.  If you have feedback about the tool, please contact Dr. Julie Adamchick at jms349@cornell.edu.   

Over 9,000 beef producers and industry leaders gathered in Nashville for the cattle industry's annual convention this week. We caught up with Ethan Lane from the National Cattlemen's Beef Association about the group's 2026 policy priorities, which include a focus on New World screwworm and trade. While New World screwworm has not been detected in the U.S., Steve Boren with Boehringer Ingelheim explains the threat of the flesh-eating parasite and how public-private partnerships are collaborating on prevention and preparedness efforts.Plus, Kevin Good with CattleFax forecasts when the cattle herd, now at a 74-year low, will start rebuilding. Kansas rancher Brandi Buzzard with High Bar Cattle Co. also joins the show to discuss her decision-making for 2026.Want to receive Newsmakers in your inbox every week? Sign up! http://eepurl.com/hTgSAD

This episode covers: Cardiology This Week: A concise summary of recent studies Lp(a) and aortic valve stenosis The truth about climate change and heart disease Snapshots Host: Emer Joyce Guests: JP Carpenter, Borge Nordestgaard, Hugh Montgomery, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/2548 Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1.  Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Hugh Montgomery has declared to have potential conflicts of interest to report: funded and runs the charity-funded non-profit 'Real Zero'. Unpaid co-chair of the UK Health Alliance on Climate Change, Lancet Countdown on Health and Climate Change. Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Borge Nordestgaard Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2548 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Doctors Lisa and Sara talk to Consultant Nephrologist Dr Darren Green about patients with Type 2 Diabetes who also have Chronic Kidney Disease and Heart Failure.  We go through a hypothetical case to illustrate some of the finer points of management that can commonly get missed or might not be appreciated. A really detailed talk full of useful practice enhancing tips for this complex group of patients.  Disclaimer: All educational content in this podcast was developed as part of the Circulation Health collaborative working project between Boehringer Ingelheim Limited, Greater Manchester Primary Care Provider Board and Health Innovation Manchester. Content has been created by Circulation Health Clinical Leads for educational purposes, reflecting NHS Clinical Lead and guideline-based recommendations. Boehringer Ingelheim had no input into content development. They have provided financial resources to support Podcast recordings related to this project. Darren would like us to make you all aware that he has working relationships with pharmaceutical industry partners. Specifically, that he has received speak fees and consultancy fees from AstraZeneca, GSK, Novartis, Boehringer Ingelheim, Bayer, and Lilly, and has been part of collaborative working agreements with Novartis, Boehringer Ingelheim, and AstraZeneca. You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: Dr Kevin Fernando counselling diabetic patients starting an SGLT2 Inhibitors like Dapagliflozin or Empagliflozin: https://www.youtube.com/watch?v=pc99SdtlsyU Diabetes UK counselling sheets on SGLT2 inhibitors: https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/sglt2-inhibitors Kidney Care UK Patient Booklets: https://kidneycareuk.org/get-support/free-resources/patient-information-booklets/ Pumping Marvellous Heart Failure Charity with patient resources: https://pumpingmarvellous.org/ International Society for Nephrology Toolkit for Initiating or Changing RAASi - Renin Angiotensin Aldosterone System Inhibitors (like ACEis such as Lisinopril or Ramipril, or ARBs like Candesartan on Losartan): https://www.theisn.org/initiatives/toolkits/raasi-toolkit/ Royal College of General Practitioners Acute Renal Failure Toolkit: https://elearning.rcgp.org.uk/course/info.php?id=899 CONFIDENCE trial: Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2410659 ATLAS trial: Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: https://pubmed.ncbi.nlm.nih.gov/11071803/ Metformin lactic acidosis Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review: https://jamanetwork.com/journals/jama/article-abstract/2084896 UK AKI Summit report UKKA AKI Summit Report + Recommendations: https://share.google/7uw1GPQ5sV2riJtiV RCGP AKI follow up  post discharge recommendations: https://bjgpopen.org/content/early/2020/06/15/bjgpopen20X101054/tab-figures-data?versioned=true ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

 Interstitial Lung Abnormality (ILA) and Interstitial Lung Disease (ILD) are often detected using CT scans and other imaging. But the definition of ILAs and how abnormalities are found throughout a patient's clinical journey continues to grow and improve. Host Eddie Qian, MD, Vanderbilt University Medical Center, discusses the importance of spotting ILAs and diagnosing ILDs earlier for better patient outcomes with experts Anna Podolanczuk, MD, Weill Cornell Medical Center, and Joe Mammarappallil, MD, Duke University. This episode is sponsored in part by Boehringer Ingelheim. Read "Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement": https://www.atsjournals.org/doi/10.1164/rccm.202505-1054ST 

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim, returns to the show during the J.P. Morgan Healthcare Conference, and following his departure from LEO Pharma (see episode 164). Brian talks about new opportunities in obesity, the benefits of private ownership in funding early science, Boehringer's deal strategy, using AI to improve commercialization efforts, and the FDA's selection of zongertinib (in patients with HER2-mutant NSCLC) for the Commissioner's National Priority Voucher program.    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

AABP Executive Director Dr. Fred Gingrich is joined by Emily Krekelberg, an educator for farm safety within the University of Minnesota extension services. This episode was developed by the AABP Mental Health and Well-Being Committee. This episode of Have You Herd? is sponsored by Boehringer Ingelheim and the PYRAMID(R) line of vaccines, a premier choice to protect calves from BRD. Get relentless protection at PyramidVaccines.com. Krekelberg defines ambiguous loss as a loss that is unclear or lacks closure. Some loss, such as death, is defined both physically (the person is no longer with us) and psychologically (we understand that the person is gone). With ambiguous loss there is an incongruence between physical and psychological loss. Krekelberg provides some examples of ambiguous loss from our everyday lives. Krekelberg discusses how ambiguous loss might look in a person and offers suggestions for how we can recognize this in our friends, family and clients. Ambiguous loss can be challenging to overcome because we do not know what we are experiencing and grief complicates this process. She also provides some suggestions for coping with ambiguous loss including understanding that conflicting feelings are normal, finding meaning and identifying the loss and discovering hope. If you are an AABP member interested in this and other mental health topics, consider joining the AABP Mental Health and Well-Being Committee by going to this page.  Resources:The Myth of Closure by Pauline Boss.  University of Minnesota Extension and type ambiguous loss in the search bar. The Moos Room podcast or find on your favorite podcast platform. 

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world's largest privately held pharma companies, Brian Hilberdink's journey is anything but conventional. Live from JPM 2026 in San Francisco, Biotech 2050 host Alok Tayi sits down with the President, U.S. Human Pharma at Boehringer Ingelheim to explore how frontline sales experience shaped a career now steering launches across obesity, chronic kidney disease, oncology, and rare disease. The pair dive into Boehringer's long-term, privately held model—one that reinvests nearly 30% of revenue into R&D—and the strategic thinking behind its ambitious pipeline: first-in-class breakthroughs in interstitial lung disease, major obesity programs, and upcoming waves of launches through 2027 and beyond. They also unpack the future of commercial pharma—from direct-to-consumer models and digital patient engagement to AI-powered launches and trial recruitment—plus Brian's candid views on China's innovation engine and the growing importance of rare disease. A masterclass in modern pharma leadership, portfolio strategy, and building for generations. Biography: Brian Hilberdink is an accomplished global executive with over 25 years of leadership experience in the pharmaceutical industry, currently serving as President of U.S. Human Pharma at Boehringer Ingelheim. In his role at Boehringer, he oversees several business units across multiple therapeutic areas, including cardiometabolic and renal diseases, obesity, pulmonary fibrosis (ILD), and oncology. Renowned for driving impactful results and fostering cultures of accountability and engagement, Brian consistently enhances organizational performance. Previously, Hilberdink served as Executive Vice President at LEO Pharma, where he led the North American Region and served as President of the U.S. affiliate, which became the primary growth driver for the company globally.. Earlier in his career, Hilberdink held several senior-level positions at Novo Nordisk, where he worked across multiple geographies. He was recognized for developing and executing innovative go-to-market strategies, resulting in the successful launch of multiple blockbuster therapies in the areas of obesity and diabetes.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a landscape marked by dynamic shifts and groundbreaking advancements in the industry.The European Union has recently taken a significant step forward by eliminating pharmaceutical export tariffs through a comprehensive free trade agreement with India. This landmark deal, nearly two decades in the making, is a strategic response to the turbulence in global markets. By potentially enhancing market access and reducing costs for drug manufacturers involved in transcontinental trade, this agreement sets a precedent for future international trade negotiations. It could also catalyze more collaborations in drug development and distribution, offering a template for how regions can work together to streamline pharmaceutical trade.Siegfried has made headlines by extending its mergers and acquisitions streak, acquiring three sites from SK Capital as part of its U.S. onshoring strategy. The acquisition of active pharmaceutical ingredient sites in Delaware, Georgia, and Australia is aimed at boosting production capabilities while reducing supply chain vulnerabilities. This move aligns with broader industry trends that emphasize geographical diversification and supply chain resilience, reflecting the industry's ongoing adaptation to global economic pressures.Meanwhile, China's National Medical Products Administration has suspended sales of Sun Pharma's dementia medication following site inspections that revealed manufacturing deficiencies. This regulatory action underscores the critical importance of compliance with stringent manufacturing standards and highlights the potential repercussions of lapses in quality control. It also demonstrates the increasing scrutiny from regulatory bodies worldwide to ensure drug safety and efficacy.On the clinical front, Roche has reported promising results for its dual GLP-1/GIP receptor agonist, showing a 22.5% weight loss at 48 weeks. This development is significant given the rising global demand for effective weight management therapies amid increasing obesity rates. The progression of this asset into phase 3 trials could herald a new class of therapeutics with substantial implications for patient care.In another strategic shift, Catalent has decided to wind down operations at its EU cell therapy manufacturing hub, reflecting a reassessment of facility utilization amidst changing market demands. This move is indicative of broader industry adjustments as companies streamline operations to focus on core competencies and emerging therapeutic areas.Turning to promising new therapies, United Therapeutics' bioengineered external liver assist system has shown potential in treating acute chronic liver failure based on early phase 1 trial results. Innovations like these highlight the transformative potential of bioengineering in addressing unmet medical needs and improving patient outcomes.Boehringer Ingelheim's significant investment in Simcere's preclinical bispecific antibody for inflammatory bowel disease underscores the industry's commitment to advancing novel therapeutic modalities. This EUR 1.05 billion deal reflects confidence in biologic therapies as essential components in managing complex chronic diseases.As we look towards 2026, biopharma companies are strategizing long-term amid evolving rules and heightened stakes. The sector is poised for transformation driven by scientific breakthroughs, regulatory challenges, and strategic alliances that promise enhanced patient care through innovative therapies. These developments reflect an industry that remains agile and resilient as it navigates complex global landscapes.In other news, Qilu Pharmaceutical's $120 million alliance with Insilico Medicine marks a significant step towards leveraging artificial intelligence (AI) for drug discSupport the show

This episode covers: Cardiology This Week: A concise summary of recent studies What´s new in TAVI?  Digital solutions in arrhythmias Mythbusters - Gratitude is heart healthy Host: Emer Joyce Guests: JP Carpenter, Davide Capodanno, Fleur Tjong Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Want to watch that extended interview on Digital solutions in arrhythmias, go to: https://esc365.escardio.org/event/2528?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

Host: Emer Joyce Guest: Fleur Tjong Want to watch that extended interview on https://esc365.escardio.org/event/2528?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

Paul Steinmetz, host of hosts, is joined today by two guests from Boehringer Ingelheim to discuss how the company cares for all of it's stakeholders as well the world at large. Michael Murphy, the Director of Sustainability, and Kristin Sugrue, the Associate Director of Boehringer Cares, came to campus from the nearby BI location in Danbury/Ridgefield to discuss what they and their company have been up to.

In this episode of Practice Life, co-hosts Travis Boston and Jessica Dunbar engage with our Business News Hour presenters — Drs. Shane Baird, Stacey Cordivano and Becky Ruemmler — for a recap of their 2026 AAEP Convention presentation. They explore the current state of the veterinary economy, highlighting that while there are challenges, the situation is not as dire as previously predicted. The conversation shifts to the evolving financial landscape for early-career veterinarians, noting a significant increase in starting salaries, and the importance of timely invoicing to improve revenue. The episode also delves into non-monetary compensation, legislative changes affecting the profession, and the critical issue of burnout among equine practitioners, emphasizing the need for better support systems and benefits packages.   Sponsored by: AAEP Practice Life is sponsored by Boehringer Ingelheim. Visit them at https://bi-animalhealth.com/equine/   

Soukaina Alaoui El Hassani (she/her) is a Moroccan‑born filmmaker and commercial producer based in New York, known for her clarity in storytelling and ability to lead creative teams through complex, high‑profile campaigns. Now a producer at Versus Creative Studio, she works across editorial, OOH, 2D animation, and CG — partnering with leading brands such as Boehringer Ingelheim, Eli Lilly and Company, MSG, Verizon, Paramount, Audible, Netflix, and more. Her sharp creative instincts, emotional intelligence, and ability to “pivot with confidence” allow her to approach production as both an art and a discipline, balancing storytelling and logistics with empathy and precision. Soukaina's mission spans commercial and independent film work: she's dedicated to championing authentic, underrepresented stories — offering new perspectives on identity, culture, and human experience. She is committed to mentorship, healthy team dynamics, and creating space for voices too often overlooked. In 2025 she was honoured as a Top Woman in Media and awarded the Creative Catalyst distinction by Cynopsis, recognizing the energy, leadership, and creative vision she brings to every collaboration.saelhassani.com

Join podcast host Takanori Yamaguchi, MD, PhD, and his guests Masato Fukunaga, MD, PhD and Masateru Takigawa, MD, PhD, for this week's Lead episode. This episode was recorded LIVE at APHRS 2025 in Yokohama, Japan. This episode was recorded entirely in Japanese. The OCEAN randomized trial found that in patients who remained free of atrial arrhythmia at least one year after successful catheter ablation for atrial fibrillation, continuing anticoagulation with rivaroxaban did not significantly reduce the risk of stroke, systemic embolism, or covert cerebral infarcts compared with low-dose aspirin, with both groups experiencing very low event rates. Additionally, rivaroxaban was associated with a higher incidence of bleeding, suggesting that long-term anticoagulation may not be necessary for many post-ablation patients with low to moderate stroke risk.   Learning Objectives Evaluate the evidence regarding the risks and benefits of continuing oral anticoagulation after successful catheter ablation for atrial fibrillation. Interpret the clinical implications of low thromboembolic event rates and increased bleeding risk when comparing anticoagulation with antiplatelet therapy in post-ablation patients. Apply study findings to clinical decision-making by identifying which patient populations may safely discontinue long-term anticoagulation after atrial fibrillation ablation.   Article Authors Atul Verma, M.D., David H. Birnie, M.D., Chenyang Jiang, M.D., Ph.D., Hein Heidbüchel, M.D., Gerhard Hindricks, M.D., Paulus Kirchhof, M.D., D.Sc., Jeff S. Healey, M.D. , Yunhe Wang, M.D., Nikolaos Dagres, M.D., Marc W. Deyell, M.D., Prashanthan Sanders, M.B., B.S., Ph.D., Rajeev K. Pathak, M.B., B.S., Ph.D., Pieter Koopman, M.D., Dieter Nuyens, M.D., Paul Novak, M.D., Guy Amit, M.D., Charles Dussault, M.D., Bhavanesh Makanjee, M.D., F. Russell Quinn, M.D., Umjeet Jolly, M.D., Leon Iden, M.D., Malte Kuniss, M.D., Mukul Sharma, M.D., Andrew Ha, M.D., Vidal Essebag, M.D., Ph.D., Jean Champagne, M.D., Michael D. Hill, M.D., Eric E. Smith, M.D., M.P.H., and George A. Wells, Ph.D., for the OCEAN Investigators   Host and Contributor Disclosure(s): T. Yamaguchi •Honoraria/Speaking/Teaching/Consulting: Abbott Japan, Japan Medtronic, Inc., Daiichi Sankyo, Boehringer Ingelheim, Bayer Healthcare Pharmaceutical, Japan, Nihon Kohden, Japan Lifeline, Novartis M. Takigawa •Honoraria/Speaking/Teaching/Consulting: Biosense Webster, Inc., Medtronic Japan, Abbott Japan •Research: Abbott, Biosense Webster, Inc., Medtronic, Inc. M. Fukunaga   •Honoraria/Speaking/Teaching/Consulting: Boston Scientific Japan, Abbott Medical   Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.

Join Digital Education Committee Member and podcast host Melissa E. Middeldorp, MPH, PhD, and her guests Helmut Pürerfellner, MD, FHRS, and Jonathan M. Kalman, MBBS, PhD, FHRS for this week's Lead episode. This episode was recorded LIVE at APHRS 2025 in Yokohama, Japan. The OCEAN randomized trial found that in patients who remained free of atrial arrhythmia at least one year after successful catheter ablation for atrial fibrillation, continuing anticoagulation with rivaroxaban did not significantly reduce the risk of stroke, systemic embolism, or covert cerebral infarcts compared with low-dose aspirin, with both groups experiencing very low event rates. Additionally, rivaroxaban was associated with a higher incidence of bleeding, suggesting that long-term anticoagulation may not be necessary for many post-ablation patients with low to moderate stroke risk.   Learning Objectives Evaluate the evidence regarding the risks and benefits of continuing oral anticoagulation after successful catheter ablation for atrial fibrillation. Interpret the clinical implications of low thromboembolic event rates and increased bleeding risk when comparing anticoagulation with antiplatelet therapy in post-ablation patients. Apply study findings to clinical decision-making by identifying which patient populations may safely discontinue long-term anticoagulation after atrial fibrillation ablation.   Article Authors Atul Verma, M.D., David H. Birnie, M.D., Chenyang Jiang, M.D., Ph.D., Hein Heidbüchel, M.D., Gerhard Hindricks, M.D., Paulus Kirchhof, M.D., D.Sc., Jeff S. Healey, M.D. , Yunhe Wang, M.D., Nikolaos Dagres, M.D., Marc W. Deyell, M.D., Prashanthan Sanders, M.B., B.S., Ph.D., Rajeev K. Pathak, M.B., B.S., Ph.D., Pieter Koopman, M.D., Dieter Nuyens, M.D., Paul Novak, M.D., Guy Amit, M.D., Charles Dussault, M.D., Bhavanesh Makanjee, M.D., F. Russell Quinn, M.D., Umjeet Jolly, M.D., Leon Iden, M.D., Malte Kuniss, M.D., Mukul Sharma, M.D., Andrew Ha, M.D., Vidal Essebag, M.D., Ph.D., Jean Champagne, M.D., Michael D. Hill, M.D., Eric E. Smith, M.D., M.P.H., and George A. Wells, Ph.D., for the OCEAN Investigators   Host and Contributor Disclosure(s):H. Purerfellner •Honoraria/Speaking/Teaching/Consulting: Biosense Webster, Inc., Abbott, Medtronic, Boehringer Ingelheim, Daiichi Sankyo, Bristol Meyers Squibb, Boston Scientific J.M. Kalman •Research: Zoll Medical Corporation, Abbott Medical, Boston Scientific •Fellowship Support: Biosense Webster, Inc., Medtronic M. Middeldorp   •Nothing to disclose. Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.    

This episode is sponsored by Boehringer Ingelheim. This episode of The Vet Blast Podcast presented by dvm360 welcomes Audrey Cook, BVM&S, MSc, MRCVS, DACVIM (SAIM), DECVIM-CA, DABVP (Feline), to talk all things feline diabetes with our host Adam Christman, DVM, MBA. 

Join podcast host Takanori Yamaguchi, MD, PhD, and his guests Koichi Magashina, MD, PhD, and Michifumi Tokuda, MD, PhD for this week's Lead episode. This episode was recorded LIVE at APHRS 2025 in Yokohama, Japan. This episode is recorded entirely in Japanese. The DECAF trial investigated whether continuing regular caffeinated coffee consumption versus complete abstinence affected the recurrence of atrial fibrillation (AF) or atrial flutter in patients after successful cardioversion. Over six months in this randomized study of 200 adults, those who drank at least one cup of caffeinated coffee daily had a significantly lower rate of AF or flutter recurrence compared to those who abstained (47% vs. 64%), suggesting moderate coffee intake may be safe and potentially beneficial for rhythm stability in this setting.    Learning Objectives Evaluate the impact of caffeinated coffee consumption versus abstinence on atrial fibrillation recurrence following cardioversion. Interpret the design and key outcomes of the DECAF randomized clinical trial and their relevance to clinical practice. Apply the trial findings to patient counseling regarding caffeine intake and atrial fibrillation management.   Article Authors Christopher X. Wong, MBBS, MPH, PhD; Christopher C. Cheung, MD, MPH; Gabrielle Montenegro, BA, Hannah H. Oo, BS; Isabella J. Peña, BA; Janet J. Tang, MPH, PhD; Samuel J. Tu, MBBS; Grace Wall, BA1; Thomas A. Dewland, MD; Joshua D. Moss, MD; Edward P. Gerstenfeld, MD; Zian H. Tseng, MD, MAS; Henry H. Hsia, MD; Randall J. Lee, MD, PhD; Jeffrey E. Olgin, MD; Vasanth Vedantham, MD; Melvin M. Scheinman, MD; Catherine Lee, PhD; Prashanthan Sanders, MBBS, PhD; Gregory M. Marcus, MD, MAS Podcast Contributors Takanori Yamaguchi, MD, PhD Koichi Magashina, MD, PhD Michifumi Tokuda, MD, PhD   Link to article Host and Contributor Disclosure(s): T. Yamaguchi Honoraria/Speaking/Teaching/Consulting: Abbott Japan, Japan Medtronic, Inc., Daiichi Sankyo, Boehringer Ingelheim, Bayer Healthcare Pharmaceutical, Japan, Nihon Kohden, Japan Lifeline, Novartis K. Nagashina   Nothing to disclose M. Tokuda   Honoraria/Speaking/Consulting: Medtronic Japan   Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.

LOVE HOSTILE TAKEOVERS? Upgrades all around the AI trade again… January Effect Defense and Oil Related – Let’s Go! PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Interactive Brokers  Warm-Up - CTP Cup - We have a winner! - Kitchen Cabinets rejoice! - Buffett is retired (kind of) - ALL TIME HIGHS - DJIA Leading so far in 2026 Markets - LOVE HOSTILE TAKEOVERS? - Upgrades all around the AI trade again... - January Effect - Defense and Oil Related! - Calling BS on Venezuela economic plans Doctor Copper - Copper surpassed $13,000 a ton for the first time due to a renewed rush to ship metal to the US. - The rally has been underpinned by the ongoing threat of import tariffs from President Donald Trump, causing US copper prices to trade at a premium to those on the London Metal Exchange. - The market has been driven by uncertainty over future US tariff policy, with analysts warning that the rest of the world could run short of copper due to low inventories outside the US. - Huge inventory build due to uncertainty Copper Chart Following up on that...Some Questions - Isn't the massive inventory build we are seeing due to uncertainly? - Lots bought before tariffs went into effect - then tariffs reduced... - Will there be a hangover from a the pull-forward like we have seen in the past? Best markets for 2025 Colombia: +80% South Korea (KOSPI): +76% Ghana: +79% Brazil (Bovespa): +34% Japan (Nikkei 225): +26% Europe STOXX 600: +19% China (Shanghai Composite): +18% U.S. S&P 500: +17% U.S. Nasdaq: +21% U.S. Dow Jones: +12% US Dollar - Basket USD is at 8 year LOW - Yen at key intervention level (again) - NO MANIPULATION HERE! -- -- Gold/Silver betting trend continues... - What happened to -> "a strong USD is in the best interests of the USA"? Monday Markets - For no apparent reason....(could it be the Venezuela news???) - Markets JUMPED - Oil and Defense stocks moved! - DJIA up ~ 600 Points ---These stocks were about 500 points of the 600: - GS Goldman Sachs Group Inc - CAT Caterpillar Inc - JPM JPMorgan Chase & Co - CVX Chevron Corp - V Visa Inc ---- GS is 1/2 the DJIA gains for 2026 Here we go... - Elon Musk's Grok is generating sexualized images of women and minors - users are taking pictures of others and telling Grok to "remove their clothes" or "put them in a thong bikini" - review of public requests sent to Grok over a single 10-minute-long period at midday U.S. Eastern Time last Friday tallied 102 attempts by X users to use Grok to digitally edit photographs of people so that they would appear to be wearing bikinis. - Politicians in France ask prosecutors to investigate; India demands answers - Experts have long warned Grok owner xAI about potential misuses of AI-generated content - Ministers in France have reported X to prosecutors and regulators over the disturbing images, saying in a statement on Friday the "sexual and sexist" content was "manifestly illegal." India's IT ministry said in a letter to X's local unit that the platform failed to prevent Grok's misuse by generating and circulating obscene and sexually explicit content. - Guardrails not very tight along the track - Surprised? TESLA - Sales awful - Stock holdingup - BYD Co. outsold Tesla Inc. in Europe's two largest electric-vehicle markets last year as the Chinese automaker continues its global expansion. - BYD registered more than twice as many new vehicles in December as Tesla did in Germany, and outperformed Tesla in the UK with 51,422 registrations compared to Tesla's 45,513. - BYD delivered 2.26 million EVs in 2025 to Tesla's 1.64 million, and has made strong inroads in the UK where Chinese brands have been attracting consumers with cheaper sticker prices. - NVDA announced it is expanding autonomous driving sector INTERACTIVE BROKERS Check this out and find out more at: http://www.interactivebrokers.com/ Silver and Gold - As we predicted - Gold and silver prices fell Wednesday after exchange operator CME Group again hiked the margins on precious metal futures. - CME Group said in a statement Tuesday that the decision was made “as per the normal review of market volatility to ensure adequate collateral coverage.” - That caused some to sell positions to bring margin requirement in check - - Should be temporary until metals find their margin equilibrium Bitcoin - Starting the year off right - Up 7% in 2026 after a very poor 2025 - Crypto moving as well - Safe haven trade, catch up trade or who-knows-what-the-hell trade? January Effect - The January Effect is a market phenomenon where stock prices—especially small-cap stocks—tend to rise more in January than in other months. - Tax-loss selling in December: Investors often sell losing positions at year-end to offset capital gains for tax purposes. - Reinvestment in January: After the new year, they buy back stocks, creating upward pressure. - Bonus and cash inflows: Year-end bonuses and new investment allocations often hit the market in January. - Small-caps up almost 3% YTD Impressive - Investors fortunate enough to own Berkshire since 1965, when Buffett took over, realized a return of about 6,100,000%, far above the S&P 500's approximately 46,000% return including dividends. - Buffett is now officially retired - said to be one (or the) greatest investors of our time - Buffett, 95, will remain chairman and plans to keep going every day to Berkshire's office in Omaha, Nebraska, about 2 miles (3.2 km) east of his home, and help Abel. - They still have not completely figured out who will run the equity portfolio after Todd Combs left to join JPM Kitchen Cabinet Relief - Steep tariffs on upholstered furniture and kitchen cabinets and vanities have been delayed by the Trump administration. - It's the latest roller coaster of Trump's tariff wars since he returned to office last year. - The administration is also scaling back on a steep tariff proposed on Italian pasta that would have put the rate at 107%. Let's talk Venezuela - The idea that the US is just going to come in an turn everything rosy is dumb - overly simplistic thesis --- Sets up a bad global potential for overthrowing governments - where does it stop - The idea that US companies are going to go in there and drill and US is going to reimburse for costs? --- The country is allied with Russia and China - not US (at this time) - This is reminiscent of when we opened the doors to Cuba - we opened it up and no one benefited. Maybe this time will be different. - BUT Venezuela owns the largest proven oil reserves in the world, holding approximately 303 billion barrels as of the end of 2024, which is nearly 18–19% of global reserves. So, that is something. VZ Oil Production Drug Price Hikes - Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration pressures them for cuts - The number of price increases for 2026 is up from the same point last year, when drugmakers unveiled plans for raises on more than 250 drugs. The median of this year's price hikes is around 4% - in line with 2025. -Drugmakers also plan to cut the list prices on around nine drugs. That includes a more than 40% cut for Boehringer Ingelheim's diabetes drug Jardiance and three related treatments. Greenland - What are the odds????? (Prediction Markets are on it! https://forecasttrader.interactivebrokers.com/eventtrader/#/market-details?id=791099793%7C20290101%7C0%7C&detail=contract_details) - “Greenland belongs to its people. It is for Denmark and Greenland, and them only, to decide on matters concerning Denmark and Greenland.” In Closing - The "AI NOT LESS PEOPLE WORKING" - Scam - “I would say that we're actually not hiring fewer people,” AMDs Lisa Su told CNBC's Jon Fortt on Tuesday from the CES conference in Las Vegas. “Frankly, we're growing very significantly as a company, so we actually are hiring lots of people, but we're hiring different people. We're hiring people who are AI forward.” Love the Show? Then how about a Donation? ANNOUNCING THE WINNER OF THE THE CLOSEST TO THE PIN 2025 Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! CTP CUP 2025 Participants: Jim Beaver Mike Kazmierczak Joe Metzger Ken Degel David Martin Dean Wormell Neil Larion Mary Lou Schwarzer Eric Harvey (2024 Winner) FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Obesity titans Novo Nordisk and Eli Lilly characteristically kicked off 2026 in the headlines. After capping 2025 with the first-ever FDA approval of an oral GLP-1 for obesity, Novo launched its Wegovy pill on Monday, starting at $149 per month out of pocket for the lower doses. Meanwhile, all eyes are on Lilly, which expects a greenlight for orforglipron as early as March. The oral weight loss play is set to be a key aspect of a pivotal year for Lilly, which hopes to more than double its annual revenue in just a few years.   Also pulling a rabbit out of a hat just before Christmas were nine drugmakers—including Amgen, Bristol Myers Squibb, Boehringer Ingelheim—which signed Most Favored Nation drug pricing agreements with the Trump administration, likely securing their businesses against the threat of tariffs. However, drug pricing will continue to be top of mind in 2026, experts told BioSpace, as only about half of Big Pharmas have signed a deal, and small and mid-sized companies haven't yet begun.   Another area biopharma leaders are watching with bated breath is the FDA. The overwhelming consensus from experts who spoke with BioSpace is that last year was a disaster—particularly from a workforce standpoint. Still, the agency approved 56 novel drugs, down just a tick from 2024's 59. Advisory committees fell off considerably, in both number and concordance, however, according to a report by Jefferies, as these meetings came under scrutiny by FDA leadership.  In 2026, will the unprecedented leadership turnover—especially at CDER—settle down? Will the new rare disease and cell and gene therapy policies bear first fruits? Also on the regulatory front, the CDC has already been busy this year, axing several childhood vaccines from its recommended schedule with potential implications for biopharma companies including Pfizer and Merck.   And if there's one area biopharma watchers anticipate even more than regulatory action, it's M&A action. Last month, analysts shared their top targets with BioSpace, listing names like Summit Therapeutics, Apogee Therapeutics and Axsome Therapeutics. Here at BioSpace, we'll stick with Viking.   Finally, don't forget to check out our NextGen Class of 2026—featuring 15 biotech startups whose mission and platforms cut through a challenging environment. And make sure to join us next week when senior editor Annalee Armstrong and news editor Dan Samorodnitsky will provide dispatches from the J.P. Morgan Healthcare Conference.  

Hermann Haller, MD, PhD President, Professor, MDI Biological Laboratory; Professor, Department of Nephrology and Hypertension, Hannover Medical School Haller received his medical degree from the Free University of Berlin and completed his postdoctoral work at Yale University. He has published more than 700 peer-reviewed articles, holds six world-wide patents and has founded four biotech companies. He has received many honors and awards and serves on numerous advisory boards, including those of Bayer, Boehringer Ingelheim, Genzyme and Novo Nordisk. In addition to his position at the MDI Biological Laboratory, he is also a full professor of medicine and former chairman of the Division of Nephrology at the Hannover Medical School in Germany. INNOVATORS is a podcast production of Harris Search Associates.      *The views and opinions shared by the guests on INNOVATORS do not necessarily reflect the views of the interviewee's institution or organization.*

Join Practice Life co-hosts Drs. Jessica Dunbar and Travis Boston as they chat with AAEP Convention attendees about the emotional rewards and practical challenges of working in horse medicine. Multiple veterinarians share that their passion is fueled by the unique bond with horses, the success of their patients, and long-term client relationships. Ultimately, you'll hear practical reflections about professional sustainability in the equine industry and how it relies on balancing high-level medical care with personal well-being and community support.   Sponsored by: AAEP Practice Life is sponsored by Boehringer Ingelheim. Visit them at https://bi-animalhealth.com/equine/   

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.In a dynamic landscape marked by both advancements and challenges, the pharmaceutical and biotech sectors continue to evolve with notable scientific, regulatory, and strategic updates. Ipsen's recent $1 billion acquisition of Simcere's preclinical LRRC15-targeting asset underscores a growing focus on antibody-drug conjugates (ADCs). These conjugates leverage the targeted action of antibodies combined with the cytotoxic effects of drugs, representing a promising approach to cancer treatment by potentially minimizing systemic toxicity. Ipsen's strategic move reflects its commitment to expanding its oncology portfolio and staying competitive within the rapidly advancing ADC landscape.AstraZeneca has been active in its pursuit of innovative cancer treatments. The company has invested $100 million in Jacobio's clinical-stage pan-KRAS inhibitor, a promising development targeting KRAS mutations prevalent in various cancers. This investment aligns with AstraZeneca's strategy to tackle challenging oncogenic targets. However, their efforts faced a setback as their Phase 3 trial for ceralasertib, an ATR inhibitor for lung cancer, failed to meet its primary endpoint. Despite this setback, AstraZeneca maintains confidence by investing significantly in promising areas like KRAS inhibitors, highlighting the inherent risks involved in pioneering novel therapeutic strategies, particularly those aiming to overcome resistance mechanisms in immuno-oncology.BioMarin has quietly discontinued its liver disease candidate amid a $4.8 billion deal with Amicus. This decision points to the complex nature of pipeline prioritization and resource allocation within high-stakes financial environments. The company's strategic shifts reflect ongoing evaluations of their development priorities in light of evolving market demands.Boehringer Ingelheim has demonstrated a commitment to renal therapeutics with a $448 million investment in Rectify Pharmaceuticals for a preclinical chronic kidney disease program. This partnership seeks to address significant unmet medical needs within kidney disease treatment. Meanwhile, Gilead Sciences has entered into a $35 million licensing agreement with Assembly Biosciences for herpes simplex virus (HSV) assets, diversifying its infectious disease portfolio and expanding its reach within antiviral therapies.Novo Holdings-backed Windward Bio's acquisition of rights to Qyun's clinical-stage immunology bispecifics for $700 million highlights robust activity in the immunology space. Bispecific antibodies are gaining traction due to their ability to target two antigens simultaneously, offering enhanced therapeutic efficacy. This acquisition illustrates ongoing interest in this area as companies seek innovative solutions to complex immunological challenges.The broader industry is also witnessing strategic partnerships such as Aditum Bio's launch of a new biotech venture with Fosun Pharma. This collaboration aims to foster novel therapies through a synergistic blend of biotechnology innovation and pharmaceutical expertise. These alliances reflect an industry trend towards collaborative efforts that leverage diverse strengths to advance therapeutic development.In regulatory news, nine major pharmaceutical companies have reached agreements with the U.S. government to lower certain drug prices in exchange for tariff relief. This development signals ongoing negotiations aimed at balancing drug affordability with industry sustainability amid growing scrutiny over pricing practices.In December 2025, significant developments emerged, impacting scientific innovation, regulatory approvals, mergers, and strategic partnerships across the industry. Notably, the U.S. Food and Drug Administration (FDA) granted early approval to Cytokinetics' MyqorzSupport the show

In this special series on Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated steatohepatitis (MASH) our host, Dr. Neil Skolnik will discuss Epidemiology, Importance, Screening, Diagnosis and Treatment of MASH. This special episode is supported by an independent educational grant from Boehringer Ingelheim. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Alina M. Allen, M.D. Associate Professor of Medicine at Mayo Clinic in Rochester, Minnesota, where she serves as the Director of Hepatology and Director of the MASLD Clinic. Selected references: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care 2025;48(7):1057–1082

In Deutschland leben etwa 9 Millionen Menschen mit einem diagnostizierten Typ-2-Diabetes. Jedes Jahr kommen ca. 450.000 Patientinnen und Patienten neu dazu: Die Belastung des Gesundheitssystems wird aller Voraussicht nach in den kommenden Jahren zunehmen. Bei vielen Betroffenen mit Diabetes mellitus treten zeitgleich Komorbiditäten auf, darunter oft kardiovaskuläre Erkrankungen bzw. chronische Nierenkrankheit. Man spricht auch vom kardiorenal-metabolischen Syndrom.

In this episode of Medsider Radio, we sat down with Andrew Holman, MD, CEO of Inmedix. Inmedix is commercializing CloudHRV, an FDA-cleared diagnostic that quantifies biological stress with clinical precision to guide treatment decisions in autoimmune disease and beyond.Andrew is a practicing rheumatologist in Seattle with 25 years of clinical and research experience. His discoveries linking autonomic dysfunction to autoimmune disease outcomes led to a $10 million patent sale to Boehringer Ingelheim. After a decade in retirement, he returned to found Inmedix and pioneer the field of immuno-autonomics — preparing the market for his technology years before launch.In this interview, Andrew shares how to build a category before commercializing a product, why clinical evidence creates competitive moats that money can't replicate, and how to raise capital from angel investors by understanding what they actually care about.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Andrew Holman.

This episode covers: Cardiology This Week: A concise summary of recent studies DAPT: how short is too short Obesity and atrial fibrillation Milestones: COURAGE  Host: Emer Joyce Guests: Carlos Aguiar, Steffen Massberg, Prash Sanders Want to watch that episode? Go to: https://esc365.escardio.org/event/2178 Want to watch that extended interview on dual antiplatelet therapy (DAPT) and shortening its optimal duration, go to: https://esc365.escardio.org/event/2178?resource=interview   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Emer Joyce, Nicolle Kraenkel and Steffen Massberg have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Prashanthan Sanders has declared to have potential conflicts of interest to report: advisory board representative University of Adelaide, Medtronic, Boston Scientific, CathRx, Abbott and Pacemate as well as research grants for University of Adelaide: Medtronic, Abbott, Boston Scientific, Becton Dickson. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

Content warning: this podcast contains frank and open discussions of substance use disorder and paths to recovery. AAEP Practice Life hosts Travis Boston and Jessica Dunbar introduce an episode focused on substance use disorder among veterinarians, an issue they highlight as sensitive and important for reducing stigma. They interview two veterinarians in recovery, Dr. Matt Moskosky and Dr. Philip Richmond, who share deeply personal, emotional stories detailing their experiences with addiction, the path to sobriety, the challenges faced within the veterinary profession, and the vital role of support systems and Physicians Health Programs (PHP/PRN) in their healing. The conversation emphasizes that addiction is common among medical professionals, not a moral failure, and encourages listeners to seek help using resources like the VIN Foundation's Vets4Vets program. Resources: VIN Foundation Vets4Vets: https://vinfoundation.org/resources/vets4vets/ Federation of State Physician Health Programs, Inc.: https://www.fsphp.org/ Substance Abuse and Mental Health Services Administration: https://www.samhsa.gov/ Recovery Research Institute: https://www.recoveryanswers.org/  Our guests' emails shared with permission: Dr. Matt Moskosky - mm@fredequine.com  Dr. Phillip Richmond - drphil@flourishingphoenix.com      Sponsored by: AAEP Practice Life is sponsored by Boehringer Ingelheim. Visit them at https://bi-animalhealth.com/equine/   

İstanbul Valiliği, tüm işletmelerde 24 saat kesintisiz ses ve görüntü kaydı yapılması zorunluluğu getirdi. Cumhurbaşkanı Erdoğan komisyonun İmralı'ya gitmesi konusunda kritik açıklamalar yaptı.Bu bölüm Boehringer Ingelheim hakkında reklam içermektedir. İÇHASDER, Boehringer Ingelheim Türkiye'nin desteğiyle diyabete dikkat çekmek için “Mavi Yeryüzü” projesini başlattı. Multidisipliner sanatçı Uğur Acil'in tasarladığı eser, diyabetin görünmez etkilerini yansıtıyor. Dünyanın ve Türkiye'nin en önemli sağlık sorunlarından biri olan diyabet hakkında ayrıntılı bilgiye buradan erişebilirsiniz.

This episode covers: Cardiology This Week: A concise summary of recent studies 'ChatGPT, MD?' - Large Language Models at the Bedside Management decisions in myocarditis Statistics Made Easy: Mendelian randomisation Host: Emer Joyce Guests: Carlos Aguiar, Folkert Asselbergs, Massimo Imazio Want to watch that episode? Go to: https://esc365.escardio.org/event/2179 Want to watch that extended interview on 'ChatGPT, MD?': Large Language Models at the Bedside? Go to: https://esc365.escardio.org/event/2179?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Folkert Asselbergs, Yasmina Bououdina, Massimo Imazio, Emer Joyce, and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Folkert Asselbergs Want to watch that episode? Go to: https://esc365.escardio.org/event/2179 Want to watch that extended interview on 'ChatGPT, MD?': Large Language Models at the Bedside? Go to: https://esc365.escardio.org/event/2179?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.  Declarations of interests: Stephan Achenbach, Folkert Asselbergs, Yasmina Bououdina, Emer Joyce, and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. E mma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology this Week: A concise summary of recent studies Lp(a) - What to expect in the very near future Myocardial infarction in older and frail adults Mythbusters: is beetroot good for your heart? Host: Rick Grobbee Guests: JP Carpenter, Vijay Kunadian, Erik Stroes Want to watch that episode? Go to: https://esc365.escardio.org/event/2177 Want to watch that extended interview on Lp(a), go to: https://esc365.escardio.org/event/2177?resource=interview   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.    Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel, Vijay Kunadian and Erik Stroes have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of groundbreaking advancements and strategic collaborations that promise to transform drug development and patient care.In the autoimmune space, Boehringer Ingelheim has made a significant move by securing a $570 million agreement with CDR-Life. This deal centers on a trispecific antibody, a novel therapeutic approach that targets multiple pathways simultaneously, potentially revolutionizing treatments for autoimmune diseases. Boehringer's commitment to these cutting-edge modalities highlights their strategy to leverage novel technologies for more effective therapeutic solutions.Similarly, Celltrion has entered a $744 million collaboration with Kaigene, focusing on two preclinical autoimmune drugs. This partnership marks Celltrion's strategic shift from biosimilars to novel biologics, positioning the company at the forefront of biologic therapeutics. By investing in early-stage research, Celltrion aims to introduce transformative therapies for autoimmune conditions, showcasing the industry's willingness to bet on groundbreaking scientific advancements.In gene editing, Azalea Therapeutics is gaining attention with its focus on permanent genome editing using a dual-vector approach. Backed by $82 million in funding and support from CRISPR pioneer Jennifer Doudna, Azalea is poised to develop potentially curative solutions through single-dose treatments. The credibility lent by a Nobel laureate adds anticipation to their research outcomes, with the potential to significantly impact gene therapy.Shifting focus to clinical trials, Sarepta Therapeutics faces challenges after missing the primary endpoint in its confirmatory trial for Duchenne muscular dystrophy drugs. Despite this setback, Sarepta is pursuing full FDA approval, emphasizing the complex interplay between clinical data and regulatory strategies. This situation underscores the critical importance of robust confirmatory trials in securing drug approvals and ensuring patient access to new therapies.Merck is making strategic moves in oncology by regaining full control over an early-phase asset and securing $700 million from Blackstone for its oncology pipeline. This dual focus on asset acquisition and financial fortification reflects Merck's aggressive growth strategy aimed at expanding its cancer treatment offerings.Emerging from stealth mode, Neok Bio has secured a $75 million investment to advance bispecific antibody-drug conjugates into clinical trials. These bispecific ADCs represent the forefront of targeted cancer therapies, aiming for precision targeting of cancer cells while minimizing off-target effects. Neok Bio's progress could significantly enhance oncology treatment paradigms through improved therapeutic indices.Turning to regulatory landscapes, Teva's recall of over half-a-million bottles of prazosin hydrochloride due to potential carcinogenic impurities highlights ongoing challenges in ensuring drug safety and quality control within manufacturing processes. Such recalls underscore the critical importance of maintaining high standards in pharmaceutical production.In broader industry developments, we see dynamic trends where scientific innovation meets strategic business decisions and regulatory considerations. The potential impact on patient care is profound, with breakthroughs in autoimmune treatments, gene editing technologies, and targeted cancer therapies poised to alter therapeutic landscapes significantly.UCB has achieved another milestone with FDA approval for Kygevvi, an ultra-rare disease medication marking their third approval in rare conditions within three years. This success underscores UCB's strategic focus on niche markets that offer less competition but significant patient impact. Advancements in genetic research aSupport the show

This month, Practice Life podcast hosts Drs. Jessica Dunbar and Travis Boston chat with Dr. Casey Cromer about the critical topic of inter-generational communication within the equine veterinary profession, covering interactions with colleagues, staff, and clients. Dr. Cromer provides a breakdown of different communication preferences, values, and characteristics associated with the Silent Generation, Baby Boomers, Generation X, Millennials, and Generation Z.  The discussion emphasizes the importance of understanding these generational differences—such as the Silent Generation's preference for formal, face-to-face communication versus Gen Z's preference for short, visual information—to improve workplace dynamics and client care, highlighting that effective communication is paramount to successful veterinary practice.   Sponsored by: AAEP Practice Life is sponsored by Boehringer Ingelheim. Visit them at https://bi-animalhealth.com/equine/   

With 15+ years leading Talent Acquisition teams in global companies like Accenture, Boehringer Ingelheim, PedidosYa and DeliveryHero, Leandro Cartelli decided to bring that expertise to new, growing businesses, so he launched Lana Talent!Leandro is passionate about helping businesses grow and succeed, and he believes it is key to find amazing talent that not only performs well but is also a perfect cultural fit. Today, his focus is on supporting small and medium-sized businesses, especially those that don't always have access to the same talent strategies as large corporations. Through Lana Talent, Leandro helps them tap into incredible talent across Latin America, his home region and one he's deeply committed to, offering not just world-class expertise, but also a smart, cost-effective way to scale.Contact Details:Email: leandro.cartelli@lanatalent.com Company: Lana TalentWebsite: https://lanatalent.com/ Social Media: LinkedIN - https://www.linkedin.com/in/leancartelli/ Remember to SUBSCRIBE so you don't miss "Information That You Can Use." Share Just Minding My Business with your family, friends, and colleagues. Engage with us by leaving a review or comment on my Google Business Page. https://g.page/r/CVKSq-IsFaY9EBM/review Your support keeps this podcast going and growing.Visit Just Minding My Business Media™ LLC at https://jmmbmediallc.com/ to learn how we can help you get more visibility on your products and services. #TalentAcquisition #RecruitmentExpert #BusinessGrowth #SMBs #HiringSolutions #LanaTalent #LatinAmericaTalent #CulturalFit #ScalingBusiness #GlobalHiring

In this special series on Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated steatohepatitis (MASH) our host, Dr. Neil Skolnik will discuss Epidemiology, Importance, Screening and treatment of MASH. This special episode is supported by an independent educational grant from Boehringer Ingelheim. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Jay Shubrook, D.O., Professor and Diabetologist in the Department of Clinical Sciences and Community Health At Touro University California College of Osteopathic Medicine Selected references: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care 2025;48(7):1057–1082